TunaCHO™ is a proprietary technology platform for CHO transient protein production. It uses suspension-adapted CHO cells (CHO-K1 parental cell line) and the process is animal-product free. It was developed by LakePharma and partners.
New flyer: Comparison of LakePharma’s two best large-scale production strategies: Hybridoma culture or Recombinant production
CHO cells originated from the same cell line used in CHO-GSN™. Together these two CHO platforms offer transient and stable production.
TunaCHO™ can be applied at various scales, ranging from 10 mL shake tubes to 10 L WAVEs. It has shown production titers greater than 2 grams per liter in shake flasks. Importantly, production titers are consistent at different scales.
Since its launch in 2017, TunaCHO™ has been used to produce over 20,000 transient productions and has become a favorite mammalian production system.
Transient recombinant antibody production in the TunaCHO™ platform. The average yield is 4.2 mg/10mL culture.
Comparison of Key Performance Features
|Expression level||10–50 mg/L||100–500 mg/L|
|Scale to reach 1 gram quantity||20-100 L||2–10 L|
|Timeline||4-6 months*||3-4 months**|
|Security of long-term supply||Unstable||Stable|
|Pathway to GMP production||Difficult||Straight forward|
|Sequence verification||Not always, lack of protection||Yes, early patent protection|
*Hybridoma timeline estimates include cell line recovery, cell culture optimization, pilot production, and large-scale production.
**Transient recombinant TunaCHO timeline estimates include hybridoma sequencing, gene synthesis, and cloning, pilot production, and large-scale production
Download flyer: Large-scale Ab Production: Hybridoma or Recombinant?
Download brochure: GMP production of antibodies & proteins for critical assays and diagnostic applications - From Development to Manufacturing in 100 days.
To learn more about our proprietary TunaCHO™ platform and detailed services download our TunaCHO™ presentation here.